This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Pfizer CFO Dave Denton Departs
Business CFO departure

Pfizer CFO Dave Denton Departs

Analysis based on 18 articles · First reported Jun 18, 2026 · Last updated Jun 18, 2026

Sentiment
-20
Attention
4
Articles
18
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market reacted negatively to the news of David Denton's departure, with Pfizer shares falling over 1% in pre-market trading and down 3.61% later in the day. This indicates investor concern regarding the leadership transition and the stability of Pfizer's financial management.

Pharmaceuticals
Event Summary

David Denton, the Chief Financial Officer of Pfizer, announced his resignation, effective August 15, 2026, to pursue an opportunity in the consumer goods industry. Pfizer has appointed Cécile Guégan, Senior Vice President, Finance, Global Biopharmaceutical Business, as the Interim Chief Financial Officer, effective August 16, 2026. The company will conduct a comprehensive internal and external search for a permanent successor. Albert Bourla, Chairman and CEO of Pfizer, acknowledged David Denton's contributions, particularly during significant business transactions like Seagen, Biohaven, and Metsera, and expressed confidence in Cécile Guégan's capabilities. Pfizer's stock experienced a decline following the announcement.

Entities Involved
stock
Pfizer
The departure of its CFO, David Denton, for an opportunity outside the pharmaceutical industry, and the appointment of Cécile Guégan as interim CFO, has led to a slight decrease in Pfizer's stock price.
Importance 100.0 Sentiment -20.0
per
David Denton
David Denton is stepping down as CFO of Pfizer to pursue a professional opportunity in the consumer goods industry, marking a significant change in his career path.
Importance 80.0 Sentiment -10.0
per
Cécile Guégan
Cécile Guégan has been named Interim Chief Financial Officer of Pfizer, effective August 16, bringing her extensive experience within the company to lead the finance organization during the transition.
Importance 70.0 Sentiment 10.0
per
Albert Bourla
Albert Bourla, Chairman and CEO of Pfizer, expressed gratitude for David Denton's leadership and confidence in Cécile Guégan's ability to lead the finance organization.
Importance 30.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.